|
|
EZRA Innovations Drug Delivery Systems sustained release drug for pharamaceuticals There are currently no reviews for this Innovation.
| EZRA Innovations Drug Delivery Systems
sustained release drug for pharamaceuticals |
|
This innovation provides the opportunity to deliver therapeutics in a well controlled manner and in some cases to take advantage of the chemical properties generate novel compounds |
 Annual Sales Forecast for USA * | Innovation Status |
Idea |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
Development
Status |
Proprietary
Protection Status |
Concept
Score |
| Ultra Low |
$1 |
$75,000 |
$1.2 M |
2 of 5
Successful Prototypes
|
2 of 5
Patent Pending
|
16 29 is
Average
|
| Low Support |
$980,000 |
$4.3 M |
$15.1 M |
| Medium Support |
$8.3 M |
$34.9 M |
$100.5 M |
| High Support |
$22.2 M |
$97.1 M |
$271.2 M |
Remaining Time & Cost to First Sale |
| Ultra High |
$43.5 M |
$182.4 M |
$525.6 M |
1-2 yrs
|
$100k-$1M
|
EZRA Innovations Drug Delivery Systems
- sustained release drug for pharamaceuticals
Final Decision Maker: Pharmaceutical Marketing and business development
Two durg formulation and pharmaceutical composition technologies are featured which allow the formulation and manufacturing of generic drugs to complete with a branded active pharmaceutical ingredient (API) which is currently off patent or about to go off patent. These proprietary technologies allow the delivery profile of the drug to be altered in a proprietary fashion yet allow the drug remain identical to its FDA approved moiety. This combination of proprietary drug delivery profile changes allows the API to harbor identical or improved therapeutic properties. This opens the opportunity to challenge large markets for various branded drugs. Thus, the featured technologies allow business development strategies with large pharmaceutical companies looking to secure extended branding opportunities for their drug. Also, generic drug manufactures can take advantage of selected formulation and composition methods to realize enhanced market share through imporved or preferred drug delivery profiles. The commercialization of selected aspects of the technology through product and moiety exclusive licensing of some products will provide the opportunity for selected regulatory development of other targeted pharmaceuticals. This business plan then involves multiple drug delivery systems which allows the opportunity to generate revenue through product specific licensing for use in managing research and development of other targeted products.
| $5-10M for licensing of drug formulation technology | Seeking: Purchase, Investment, Manufacturing/R&D |
|
* Consumption sales forecast. Does not include "Random" events or "Inventory Fill". Forecast is for Year 1 for Large or Year 2 for Small Companies.
Forecast should be read as ..."With Low marketing support there is an 80% odds of achieving sales of at least... |
| Listing #: USA.76.031709.011 |
Page 1 of 5 |
Date Posted: 2009-03-27 |
|
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Report Assumptions and Inventor(s) Commentary
|
|
| Inventor(s) Assumptions |
"Most Likely"
Estimate |
Confidence |
Inventor(s) Commentary
Data Source or Basis for Assumptions |
| # of Possible Final Decision Makers |
1,100 |
60% |
Decision makers with be all Pharmaceutical Companies with certain drugs losing patent coverage and generic drug makers wishing a market advantage for their drugs.
|
| Revenue per First Purchase |
$7,000,000.00 |
50% |
license deal with large to midsized pharmaceutical company based on size of market for drug which is near patent expiration or large generic looking to brand its drug. |
| % that will Repeat |
N/A |
N/A |
|
| Number of Annual Repeats |
N/A |
N/A |
|
| Revenue per Repeat Purchase |
N/A |
N/A |
|
| Reseller (Trade) Margin |
40% |
60% |
These are standard terms for the type of activity for a pharmaceutical license. Market conditions and competors could push the respective numbers down slightly. |
| Producer Profit (EBITD) |
40% |
50% |
For a straight license deal the margin is expected to be significantly higher than indiicated above. The numbers listed represent the development of an ANDA and a generic product. |
| |
| Innovation Status |
|
Development
Status |
2 of 5
Successful Prototypes
|
A busines model based drug delivery sysems using proprietary technologies, accelerated FDA clearance and a disruptive market strategy targeting branded and generic pharmaceuticals |
| Cost to First Sale (remaining) |
$100k-$1M |
40% |
There are two forms of first sale. A straight licensing deal to use IP.Costs are minimal. The second is a clinical ANDA which will require about $4M. |
| Time to First Sale (remaining) |
1-2 yrs |
40% |
A license deal if secured that would constitute a first sale. Currently in third round talks with pharma to review this. Could occur in months. ANDA would take 3 yrs. |
| Confidence in Concept Claims made in description |
60% |
New compounds will be generated which change the composition and drug release properies of a preveiously approved drug.The composition and therapy of the active drug is unchanged. |
Proprietary
Protection Status |
2 of 5
Patent Pending
|
Claims that allow delivery changes of pharmaceutical products with out changing altering their therapeutic indications, expand their therapeutic benefit and extend patent life. |
| Concept Score & Diagnostics |
|
|
| Concept Diagnostics |
Red |
Yellow |
Green |
| Percentile Group |
Bottom 40% |
Middle 40% |
Top 20% |
| Overt Benefit |
 |
|
|
| Reason to Believe |
|
|
|
| Dramatic Difference |
|
|
|
|
| Listing #: USA.76.031709.011 |
Page 2 of 5 |
Date Posted: 2009-03-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Inventor Commentary & Alternative Development Scenarios
|
|
| Inventor(s) Sales Goals |
| Minimum Goal |
$1 M |
Current GOAL |
$5 M |
Inventor(s) Commentary:
The pharmaceutical market place is in trouble as pipelines of new drug candidates dry up. Big pharma is merging to combat this. Small biotechnology companies as sources of product leads are strapped for funding. In the present business model, proprietary methods offer both the large and small drug companies the opportunity to extend their presence in market as branded products or the chance to develope a "better generic" form of a drug through a proprietary delivery system. |
|
CURRENT SALES FORECAST |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$1 |
$75,000 |
$1.2 M |
| Low Support |
$980,000 |
$4.3 M |
$15.1 M |
| Medium Support |
$8.3 M |
$34.9 M |
$100.5 M |
| High Support |
$22.2 M |
$97.1 M |
$271.2 M |
| Ultra High |
$43.5 M |
$182.4 M |
$525.6 M |
If MARKETING CONCEPT Improved (Increase Concept Score by +20 Points) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$3 |
$240,000 |
$3.0 M |
| Low Support |
$3.2 M |
$12.2 M |
$35.1 M |
| Medium Support |
$27.8 M |
$93.2 M |
$224.0 M |
| High Support |
$76.7 M |
$259.7 M |
$611.1 M |
| Ultra High |
$145.8 M |
$487.8 M |
$1.1 B |
If MARKETING CONCEPT and PRODUCT/SERVICE Improved (Increase Concept +20 Points, Repeat Rate & Number of repeats by 30% and Revenue per purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$3 |
$240,000 |
$2.9 M |
| Low Support |
$3.3 M |
$12.3 M |
$35.0 M |
| Medium Support |
$28.0 M |
$95.3 M |
$223.3 M |
| High Support |
$76.3 M |
$259.7 M |
$617.4 M |
| Ultra High |
$146.8 M |
$494.6 M |
$1.2 B |
|
| Listing #: USA.76.031709.011 |
Page 3 of 5 |
Date Posted: 2009-03-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Details
|
|
| Fair Market Royalty (%) |
| |
Conservative - 80% Odds
Royalty Percentage |
Most Likely - 50% Odds
Royalty Percentage |
Aggressive - 20% Odds
Royalty Percentage |
| At CURRENT State & Status |
3% |
4.8% |
6.9% |
Sales & Marketing
Support Level |
Annual Inventor Royalty Revenue |
3 Year Value
to Inventor
If 50% Odds |
| 80% Odds |
50% Odds |
20% Odds |
| Ultra Low Support |
$3,400 |
$9,900 |
$21,000 |
$30,000 |
| Low Support |
$62,000 |
$160,000 |
$330,000 |
$490,000 |
| Medium Support |
$440,000 |
$1.2 M |
$2.3 M |
$3.5 M |
| High Support |
$1.2 M |
$3.2 M |
$6.3 M |
$9.6 M |
| Ultra High Support |
$2.4 M |
$6.3 M |
$12.0 M |
$18.8 M |
| Sales & Marketing Support Level Assumptions |
| Sales & Marketing Support Level Assumptions |
Sample Numbers |
% Aware x
% Distribution
(Aware & Able) |
Inventor
Confidence |
| % Distribution |
% Awareness |
| Ultra Low Support (Word of Mouth) |
5% |
3% |
0.2% |
N/A |
| Low Support (Small Company) |
20% |
10% |
2% |
N/A |
| Medium Support (Medium Sized Company) |
50% |
25% |
13% |
% |
| High Support (Large Company) |
75% |
45% |
34% |
N/A |
| Ultra High Support (Mega or Niche) |
90% |
70% |
63% |
N/A |
|
Graph of EQUIVALENT (Awareness x Distribution) Combinations
 |
NAICS Industry Codes
For This Invention |
| 54171 - Research and Development in the Physical, Enginee... |
| 54199 - All Other Professional, Scientific, and Technical... |
| |
| |
| |
|
| Patent Numbers that apply to this Product/Service |
| 7,498,329 |
| 4,606,909 |
| 4,083,749 |
| 4,173,626 |
| 4,193,985 |
|
| Inventor(s) PEDIGREE |
| Years EXPERIENCE in related industry |
25 |
| GRANTED Patents |
0 |
| Licensing Deals SIGNED |
2 |
| Innovations that have SHIPPED |
0 |
|
For USA Patents: Utility Patent = 7 digit number, Design Patent starts with D, Planet Patent starts with PP. Provisional Application "61/xxx,xxx", Non provisional application "12/xxx,xxx", Design patent application "29/xxx,xxx"
|
|
CAUTION: This Merwyn Business Simulation Research Report includes no warranty or guarantee. Results and opinions should be considered rough and directional in nature. This is because the report is based upon inventor-supplied data and simplified modeling methods. If you are looking to invest, distribute, purchase or become involved with this innovation, in any way, we strongly urge you to validate the inventor data and sales forecasts BEFORE committing yourself or your resources. Merwyn Research, Inc. shall not be responsible for any liability or damages arising out of the failure to perform such investigation and validation. Changes in the concept description, product, pricing, or input assumptions will almost certainly change results.
|
| Listing #: USA.76.031709.011 |
Page 4 of 5 |
Date Posted: 2009-03-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Forecasts for Other Countries
|
|
 Annual Sales - Probability Forecast - Canada |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$12,000 |
$180,000 |
| Low Support |
$160,000 |
$680,000 |
$2.4 M |
| Medium Support |
$1.3 M |
$5.5 M |
$15.9 M |
| High Support |
$3.5 M |
$15.4 M |
$43.0 M |
| Ultra High |
$6.9 M |
$28.9 M |
$83.3 M |
 Annual Sales - Probability Forecast - United Kingdom |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$21,000 |
$330,000 |
| Low Support |
$280,000 |
$1.2 M |
$4.2 M |
| Medium Support |
$2.3 M |
$9.8 M |
$28.3 M |
| High Support |
$6.3 M |
$27.3 M |
$76.3 M |
| Ultra High |
$12.2 M |
$51.3 M |
$147.8 M |
Forecast are calculated based on population, (PPP) purchasing power parity, International Trade, Urbanization and the Human Growth Index.
Forecast can be skewed for some industries, so for best results, adjusting the number of final decision makers for every country is recommended.
| Listing #: USA.76.031709.011 |
Page 5 of 5 |
Date Posted: 2009-03-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
